Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1906-1914

  Herben, Virginie M M ^a   Gijn, Roel Van ^a   Schellens, Jan H M ^a   Schot, Margaret ^a   Lieverst, Jan ^a   Hillebrand, Michel J X ^a   Schoemaker, Nadja E ^a   Porro, Maria Grazia ^a   Beijnen, Jos H ^a   Ten Bokkel Huinink, Wim W ^a  

^a Italy

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; MANNITOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG FORMULATION; DRUG HALF LIFE; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 0033001688     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1906     Document Type: Article

References (31)

1. Hsiang Y-H, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14875, 1985
2. Hsiang Y-H, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
3. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
4. Pantazis P, Hinz HR, Mendoza JT, et al: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52:3980-3987, 1992
5. Supko JG, Plowman J, Dyker DJ, et al: Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Assoc Cancer Res 33:432, 1992 (abstr)
6. Rubin E, Wood V, Bharti A, et al: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1:269-276, 1995
7. Dahut W, Harold N, Takimoto C, et al: Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14:1236-1244, 1996
8. Siu LL, Oza AM, Eisenhauer EA, et al: Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. J Clin Oncol 16:1122-1130, 1998
9. Hochster H, Liebes L, Speyer J, et al: Phase I and pharmacodynamic study of prolonged infusion 9-amino-camptothecin in two formulations. Proc Am Soc Clin Oncol 16:201a, 1997 (abstr)
10. Tran HT, Madden T, Newman RA, et al. Phase I pharmacokinetic trial of 9-aminocamptothecin given as a 15 minute infusion daily × 5 for 2 to 4 weeks. Proc Am Assoc Cancer Res 39:522, 1998 (abstr)
11. De Jonge MJA. Punt CJA, Sparreboom A, et al: Phase I and pharmacologic study on oral (PEG 1000) 9-amino-camptothecin in patients with advanced solid tumors. Ann Oncol 9:64, 1998 (abstr)
12. Creemers GJ, Lund B, Verweij J: Topoisomerase I inhibitors: Topotecan and irenotecan. Cancer Treat Rev 20:73-96, 1994
13. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
14. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
15. Van Gijn R, Herben VMM, Hillebrand MJX, et al: High-performance liquid chromatography analysis of 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro volumes of human plasma. J Pharm Biomed Anal 17:1257-1265, 1998
16. Holford NHG, Sheiner LB: Kinetics of pharmacologic response. Pharmacol Ther 16:143-166, 1992
17. Minami H, Mick R, Vokes EE, et al: Pharmacodynamic models for leukopenia and thrombocytopenia of 9-aminocamptothecin. Proc Am Soc Clin Oncol 15:179, 1996 (abstr)
18. Liang MD, Dahut W, Quinn MF, et al: Preclinical and clinical studies of a new colloidal dispersion formulation of 9-aminocamptothecin. Proc Am Assoc Cancer Res 37:432, 1996 (abstr)
19. Takimoto CH, Dahut W, Marino MT, et al: Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 15:1492-1501, 1997
20. Takimoto CH, Dahut W, Harold N, et al: A phase I trial of a prolonged infusion of 9-aminocamptothecin in adult patients with solid tumors. Proc Am Soc Clin Oncol 15:488, 1996 (abstr)
21. Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499-1507, 1993
22. Verweij J, Lund B, Beijnen J, et al: Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4:673-678, 1993
23. Rowinsky EK, Grochow LB, Hendriks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
24. Burris HA III, Awada A, Kuhn JG, et al: Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs 5:394-402, 1994
25. Van Warmerdam LJC, Ten Bokkel Huinink WW, Rodenhuis S, et al: Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion [published erratum appears in J Clin Oncol 14:689, 1996]. J Clin Oncol 13:1768-1776, 1995
26. Blaney SM, Balis FM, Cole DE, et al: Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 53:1032-1036, 1993
27. Hoskins P, Eisenhauer E, Beare S, et al: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 16:2233-2237, 1998
28. Hochster H, Liebes L, Speyer J, et al: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553-559, 1994
29. Creemers GJ, Gerrits CJH, Schellens JHM, et al: Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 14:2540-2545, 1996
30. Pazdur R, Diaz-Canton E, Ballard WP, et al: Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 15:2905-2909, 1997
31. Saltz LB, Kemeny NE, Tong W, et al: 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer 80:1727-1732, 1997